Junko Matsuzaki

Title: Junko Matsuzaki: Innovator in Cancer Therapy

Introduction

Junko Matsuzaki is a prominent inventor based in Williamsville, NY (US). She has made significant contributions to the field of cancer therapy through her innovative research and patented technologies. With a total of 4 patents, her work focuses on enhancing the efficacy of cancer treatments.

Latest Patents

One of Junko Matsuzaki's latest patents is titled "Compositions and methods for use of recombinant T cell receptors for direct recognition of tumor antigen." This patent provides compositions and methods for the prophylaxis and therapy of various cancers that express the NY-ESO-1 antigen. The invention includes recombinant T cell receptors (TCRs), polynucleotides encoding them, and expression vectors that facilitate the introduction of these polynucleotides into cells. The modified cells, including CD4T cells, CD8T cells, natural killer T cells, γδ T cells, and progenitor cells, are capable of directly recognizing cancer cells expressing the NY-ESO-1 antigen. This recognition occurs through human leukocyte antigen (HLA) class II-restricted binding of the TCR to the antigen, without the need for antigen presentation by antigen-presenting cells. The patent also outlines methods for creating expression vectors and identifying TCRs for therapeutic applications.

Career Highlights

Junko Matsuzaki is associated with Health Research, Inc., where she continues to advance her research in cancer therapies. Her innovative approaches have the potential to significantly impact the treatment landscape for patients with cancer.

Collaborations

Some of her notable coworkers include Takemasa Tsuji and Kunle Odunsi, who collaborate with her on various research initiatives.

Conclusion

Junko Matsuzaki's contributions to cancer therapy through her patented inventions highlight her role as a leading innovator in the field. Her work not only advances scientific understanding but also offers hope for improved cancer treatments.